AzTrials
AzTrials

Growth FailureOPTIGROWNCT02999945

Optimal Growth of Preterm Infants With Growth Restriction

A study testing SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients in people with Growth Failure and Adiposity, run by Medical University of Vienna.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced… Read more about this study

Who is it for?
Ages Up to 42 weeksHealthy volunteers can take part
Conditions the study is for
Growth Failure, Adiposity, Diabetes
What is being tested?
SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
Mar 2019to Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 42 weeks
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Preterm infants with a birth weight <1500g and birth weight <10th percentile.
  • Weight at term <10th percentile
  • Informed consent

Who cannot join

  • Genetic or metabolic diseases with the primary effect on growth
  • Necrotizing enterocolitis
  • Intraventricular hemorrhage (IVH) >Grade II
  • Periventricular leukomalacia (PVL) Stage III
  • Genetic or metabolic disorders
  • Bronchopulmonary dysplasia

About this study

Official title: Body Composition, Metabolic Programming and Long Term Outcome of Growth Restricted Preterm Infants Under Different Nutritional Management A Prospective Randomized Controlled Multicenter Trial

In this prospective randomized controlled multi center trial the investigators stratify "Very Low Birthweight " (VLBW)-infants with growth retardation in small for gestational age (SGA) or intrauterine growth restricted (IUGR) - infants and aim to investigate the impact of a nutritional management with enhanced nutrients from discharge up to the 52nd week of postconceptional age on growth, body composition, metabolic programming, metabolomics, microbiome and long term neurodevelopmental outcome. In this study, the investigators will evaluate the difference in metabolic profiles of SGA and IUGR preterm infants. The investigators will further longitudinally assess, how different nutritional interventions affect the altered pathways in the first year of life and identify, in combination with data available from metabolic markers, microbiome and breast milk analysis, potential pathways resulting in increased disease risk later in life.

Read the detailed description

Prematurity is the leading cause for mortality and morbidity in newborns with very low birth weight (VLBW) infants (< 1500g birth weight) at highest risk. Ten to thirty percent of VLBW infants are also born too small for their gestational age defined by a birth weight below the 10th percentile. In daily neonatal intensive care, consequential long term-follow up and most studies all growth restricted premature infants are treated the same, importantly this includes the nutritional management after birth. However, different groups of patients with different causal pathologies are subsumed under the definition growth restriction or born too small. One group of growth restricted patients refers to the infants born constitutionally small or small for gestational age (SGA). The other group refers to infants with an intrauterine growth restriction (IUGR) caused by a complex antenatal pathology. Consequently, the nutritional management after birth is very important to minimize the potential risk for developing obesity, diabetes and cardiovascular diseases later in life and to achieve optimal growth. So far we do not consider the different underlying pathomechanisms of growth restriction in our nutritional concepts for preterm infants and therefore cause long-term consequences. The European society of pediatric gastroenterology, hematology and nutrition (ESPGHAN) recommends to feed enhanced nutrients up to 52nd week of gestation in all growth restricted preterm infants- regardless if they are SGA or IUGR premature. Actually, reliable data guaranteeing that the recommended "enhanced nutrients strategy" providing extra nutrients up to 52 weeks for SGA and IUGR infants is safe and effective for both groups in terms of long-term growth and metabolic programming are lacking.

A total of 348 preterm infants born and discharged below the 10th percentile at term will be included in the study and stratified according to SGA or IUGR by a combination of antenatal ultrasound parameters and growth parameters (including 10% screening failures and 20% drop out. Furthermore IUGR and SGA growth restricted preterm infants will be stratified according to breastfeeding or formula feeding and randomized in one of the following groups: Standard nutrients group (breastfeeding or starter formula) or Enhanced nutrients group (fortified breast milk or post-discharge formula. Body composition measurements will be performed by air displacement plethysmography - a non-invasive method. Anthropometric measurements will be performed by measuring weight, height and head circumference. Furthermore, parameters of metabolic programming, metabolomics, the stool microbiome and neurodevelopmental outcome will be determined. Additionally, the stool microbiome will be characterized from infant stool samples and compared between the two groups. After an interventional period of three months infants will be followed up until 2 years of age.

Being tested
SGA-enhanced nutrients, IUGR-enhanced nutrients, SGA-standard nutrients, IUGR-standard nutrients
Keywords
preterm infants, SGA infants, IUGR infants, growth, body composition, metabolomics, microbiome, adiposity markers, metabolic programming, neurodevelopmental outcome
Medical subject headings
Failure to Thrive, Obesity, Diabetes Mellitus, Neurologic Manifestations

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SGA-enhanced nutrientsDietary supplement

    Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

  • IUGR-enhanced nutrientsDietary supplement

    Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

  • SGA-standard nutrientsOther

    Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)

  • IUGR-standard nutrientsOther

    Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)

Study groups in NCT02999945
Study groupRoleWhat they receive
SGA-enhanced nutrientsActive comparatorInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
Receives: Dietary Supplement: SGA-enhanced nutrients
SGA-standard nutrientsOtherInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
Receives: Other: SGA-standard nutrients
IUGR-enhanced nutrientsActive comparatorInfants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
Receives: Dietary Supplement: IUGR-enhanced nutrients
IUGR-standard nutrientsOtherInfants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
Receives: Other: IUGR-standard nutrients

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fat Free Mass

    Fat free mass measured by body plethysmography

    Measured: 3 months

Secondary outcomes (15)
  1. anthropometry-length

    length in cm

    Measured: 24 months

  2. anthropometry-weight

    weight in grams

    Measured: 24 months

  3. anthropometry-HC

    head circumference in cm

    Measured: 24 months

  4. anthropometry-z-score

    z-scores

    Measured: 24 months

  5. parameters of metabolic programming- IGF1

    IGF-1in ng/ml

    Measured: 12 months

  6. parameters of metabolic programming-IGF3

    IGF-3 in ng/ml

    Measured: 12 months

  7. parameters of metabolic programming-IGF-BP

    IGF-BP in ng/ml

    Measured: 12 months

  8. parameters of metabolic programming-Leptin

    Leptin in ng/ml

    Measured: 12 months

  9. parameters of metabolic programming-Adiponectin

    Adiponectin in mcg/ml

    Measured: 12 months

  10. neurodevelopmental outcome

    Bayley scales

    Measured: 24months

  11. metabolomics

    Metabolomic analysis will determine around 200 metabolites covering polar lipids (SOFIA), acylcarnitines (CARN), non-esterified fatty acids (NEFA) and amino acids (AA). Data will be acquired according to retention time and mass transition on triple quadrupole mass spectrometer, controlled by Analyst.

    All metabolite concentrations are reported in µmol/L

    Measured: 12 months

  12. stool microbiome

    Measured: 24 months

  13. macronutrients in breastmilk-fat

    Fat will be analysed by modified Mojonnierether extraction (g/100ml)

    Measured: 6 months

  14. macronutrients in breastmilk-Lactose

    Lactose will be determined by Lactose analysis method: LC-MS/MS (g/100ml)

    Measured: 6 months

  15. macronutrients in breastmilk-protein

    Protein will be determined by elemental analysis (g/100ml)

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Dec 2016 (estimated)
  2. Study startMar 2019 (estimated)
  3. Primary completionJan 2020 (estimated)
  4. Study completionJan 2022 (estimated)

Why it stopped: no funding

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02999945
Sponsor's protocol ID
OPTIGROW
Acronym
OPTIGROW
Status last verified
Mar 2019
First submitted
5 Dec 2016
Last updated
21 Mar 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing SGA-enhanced nutrients, IUGR-enhanced nutrients and SGA-standard nutrients in people with Growth Failure and Adiposity, run by Medical University of Vienna.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 21 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fat Free Mass (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in